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Restenosis After Sirolimus-Eluting Stent Implantation:
Long-Term Evaluation Following Repeat Percutaneous Intervention
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Background: Restenosis after sirolimus-eluting stent (SES) implantation has been shown to occur in a small but sizeable proportion of cases. Currently, the best management of patients with post-SES restenosis remains undefined. Study Population: From April 2002, drug-eluting stent implantation has been adopted as the default strategy in our institution, without clinical or anatomical restrictions. During 6 months enrollment, a total of 631 patients received at least one SES. From these, 22 consecutive patients have undergone subsequent repeat percutaneous intervention to treat post-SES restenosis. The long-term outcomes after the re-treatment are reported.
Results:
Patients with post-SES restenosis treated with repeat percutaneous intervention were frequently diabetics (46%). Re-treatment was performed after a median time of 204 days from the index procedure. Most patients were re-treated with implantation of another drug-eluting stent at the restenotic site: new SES implantation in 10 patients (46%), and paclitaxel-eluting stent implantation (46%). The remaining 2 patients were treated with plain balloon dilatation and bare stent implantation respectively. After a median follow-up of 131 days, the incidence of death, myocardial infarction, or re-intervention was zero. One-year follow-up will be available at the presentation.Conclusions: Percutaneous re-treatment of post-SES restenosis utilizing repeat drug-eluting stent implantation as the strategy of choice appears to be safe and associated with very low incidence of recurrence at medium-term follow-up. 
